These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 18042711)

  • 1. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.
    Nikiforov MA; Riblett M; Tang WH; Gratchouck V; Zhuang D; Fernandez Y; Verhaegen M; Varambally S; Chinnaiyan AM; Jakubowiak AJ; Soengas MS
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19488-93. PubMed ID: 18042711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.
    Fernández Y; Verhaegen M; Miller TP; Rush JL; Steiner P; Opipari AW; Lowe SW; Soengas MS
    Cancer Res; 2005 Jul; 65(14):6294-304. PubMed ID: 16024631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.
    Wirth M; Stojanovic N; Christian J; Paul MC; Stauber RH; Schmid RM; Häcker G; Krämer OH; Saur D; Schneider G
    Nucleic Acids Res; 2014; 42(16):10433-47. PubMed ID: 25147211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells.
    Qin JZ; Ziffra J; Stennett L; Bodner B; Bonish BK; Chaturvedi V; Bennett F; Pollock PM; Trent JM; Hendrix MJ; Rizzo P; Miele L; Nickoloff BJ
    Cancer Res; 2005 Jul; 65(14):6282-93. PubMed ID: 16024630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
    Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
    Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC-induced sensitivity of human malignant melanoma to proteasome inhibitors - a KaMYCaze effect.
    Fuchs SY
    Pigment Cell Melanoma Res; 2008 Feb; 21(1):9-10. PubMed ID: 18353138
    [No Abstract]   [Full Text] [Related]  

  • 7. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
    Gomez-Bougie P; Wuillème-Toumi S; Ménoret E; Trichet V; Robillard N; Philippe M; Bataille R; Amiot M
    Cancer Res; 2007 Jun; 67(11):5418-24. PubMed ID: 17545623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
    Nawrocki ST; Carew JS; Maclean KH; Courage JF; Huang P; Houghton JA; Cleveland JL; Giles FJ; McConkey DJ
    Blood; 2008 Oct; 112(7):2917-26. PubMed ID: 18641367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.
    Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA
    PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.
    Qin JZ; Xin H; Sitailo LA; Denning MF; Nickoloff BJ
    Cancer Res; 2006 Oct; 66(19):9636-45. PubMed ID: 17018621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1.
    Ri M; Iida S; Ishida T; Ito A; Yano H; Inagaki A; Ding J; Kusumoto S; Komatsu H; Utsunomiya A; Ueda R
    Cancer Sci; 2009 Feb; 100(2):341-8. PubMed ID: 19068089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
    Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
    J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin complex 1 (mTORC1) enhances bortezomib-induced death in tuberous sclerosis complex (TSC)-null cells by a c-MYC-dependent induction of the unfolded protein response.
    Babcock JT; Nguyen HB; He Y; Hendricks JW; Wek RC; Quilliam LA
    J Biol Chem; 2013 May; 288(22):15687-98. PubMed ID: 23612979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins.
    Wolter KG; Verhaegen M; Fernández Y; Nikolovska-Coleska Z; Riblett M; de la Vega CM; Wang S; Soengas MS
    Cell Death Differ; 2007 Sep; 14(9):1605-16. PubMed ID: 17541428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells.
    Baou M; Kohlhaas SL; Butterworth M; Vogler M; Dinsdale D; Walewska R; Majid A; Eldering E; Dyer MJ; Cohen GM
    Haematologica; 2010 Sep; 95(9):1510-8. PubMed ID: 20378569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib.
    Chen S; Blank JL; Peters T; Liu XJ; Rappoli DM; Pickard MD; Menon S; Yu J; Driscoll DL; Lingaraj T; Burkhardt AL; Chen W; Garcia K; Sappal DS; Gray J; Hales P; Leroy PJ; Ringeling J; Rabino C; Spelman JJ; Morgenstern JP; Lightcap ES
    Cancer Res; 2010 Jun; 70(11):4318-26. PubMed ID: 20460535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
    Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
    J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells.
    Mannava S; Zhuang D; Nair JR; Bansal R; Wawrzyniak JA; Zucker SN; Fink EE; Moparthy KC; Hu Q; Liu S; Boise LH; Lee KP; Nikiforov MA
    Blood; 2012 Feb; 119(6):1450-8. PubMed ID: 22144178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.
    Kern J; Untergasser G; Zenzmaier C; Sarg B; Gastl G; Gunsilius E; Steurer M
    Blood; 2009 Oct; 114(18):3960-7. PubMed ID: 19713465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells.
    Smith AJ; Dai H; Correia C; Takahashi R; Lee SH; Schmitz I; Kaufmann SH
    J Biol Chem; 2011 May; 286(20):17682-92. PubMed ID: 21454712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.